The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: Diversified control of cell growth, inflammation, and injury

Histology and Histopathology

Volumn 22, Issue 10-12, 2007, Pages 1251-1267

  Chong, Z Z ^a   Maiese, Keneth ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Akt; Alzheimer's; Apoptosis; Cancer; Diabetes; ERK; Erythropoietin; Gab1; Inflammation; Jak2; JNK; MAP kinase; Nuclear factor B; Oxidative stress; SHP1; SHP2; Src homology; STAT; Stem cells; Tyrosine phosphatases

Indexed keywords

ANGIOTENSIN II; ERYTHROPOIETIN; GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE SHP 1; PROTEIN TYROSINE PHOSPHATASE SHP 2; RECOMBINANT ERYTHROPOIETIN; RESVERATROL; STAT PROTEIN; STRESS ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE, NON RECEPTOR TYPE 11; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; PTPN6 PROTEIN, HUMAN; SIGNAL PEPTIDE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANEMIA; APOPTOSIS; CANCER; CELL DAMAGE; CELL FUNCTION; CELL GROWTH; CELL MATURATION; CELL PROTECTION; CELL SURVIVAL; CHEMOTAXIS; DIABETES MELLITUS; HEMODIALYSIS PATIENT; HUMAN; INFLAMMATION; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; CELL PROLIFERATION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

APOPTOSIS; CELL PHYSIOLOGY; CELL PROLIFERATION; HUMANS; INFLAMMATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PROTEIN-TYROSINE-PHOSPHATASE; SHP1 PROTEIN TYROSINE PHOSPHATASE;

EID: 34748831102     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (215)

1. Akagi S., Ichikawa H., Okada T., Sarai A., Sugimoto T., Morimoto H., Kihara T., Yano A., Nakao K., Nagake Y., Wada J. and Makino H. (2004). The critical role of SRC homology domain 2-containing tyrosine phosphatase-1 in recombinant human erythropoietin hyporesponsive anemia in chronic hemodialysis patients. J. Am. Soc. Nephrol. 15, 3215-3224.
2. Alonso A., Sasin J., Bottini N., Friedberg I., Osterman A., Godzik A., Hunter T., Dixon J. and Mustelin T. (2004). Protein tyrosine phosphatases in the human genome. Cell 117, 699-711.
3. Altomare D.A., Guo K., Cheng J.Q., Sonoda G., Walsh K. and Testa J.R. (1995). Cloning, chromosomal localization and expression analysis of the mouse Akt2 oncogene. Oncogene 11, 1055-1060.
4. Andersen J.N., Jansen P.G., Echwald S.M., Mortensen O.H., Fukada T., Del Vecchio R., Tonks N.K. and Moller N.P. (2004). A genomic perspective on protein tyrosine phosphatases: gene structure, pseudogenes, and genetic disease linkage. FASEB J. 18, 8-30.
5. Aoki Y., Huang Z., Thomas S.S., Bhide P.G., Huang I., Moskowitz M.A. and Reeves S.A. (2000). Increased susceptibility to ischemia-induced brain damage in transgenic mice overexpressing a dominant negative form of SHP2. FASEB J. 14, 1965-1973.
6. Araki T., Nawa H. and Neel B.G. (2003). Tyrosyl phosphorylation of Shp2 is required for normal ERK activation in response to some, but not all, growth factors. J. Biol. Chem. 278, 41677-41684.
7. Bahlmann F.H., Song R., Boehm S.M., Mengel M., von Wasielewski R., Lindschau C., Kirsch T., de Groot K., Laudeley R., Niemczyk E., Guler F., Menne J., Haller H. and Fliser D. (2004). Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 110, 1006-1012.
8. Bard-Chapeau E.A., Yuan J., Droin N., Long S., Zhang E.E., Nguyen T.V. and Feng G.S. (2006). Concerted functions of Gab1 and Shp2 in liver regeneration and hepatoprotection. Mol. Cell. Biol. 26, 4664-4674.
9. Benzing W.C., Wujek J.R., Ward E.K., Shaffer D., Ashe K.H., Younkin S.G. and Brunden K.R. (1999). Evidence for glial-mediated inflammation in aged APP(SW) transgenic mice. Neurobiol. Aging. 20, 581-589.
10. Berchtold S., Volarevic S., Moriggl R., Mercep M. and Groner B. (1998). Dominant negative variants of the SHP-2 tyrosine phosphatase inhibit prolactin activation of Jak2 (janus kinase 2) and induction of Stat5 (signal transducer and activator of transcription 5)-dependent transcription. Mol. Endocrinol. 12, 556-567.
11. Berg K.L., Siminovitch K.A. and Stanley E.R. (1999). SHP-1 regulation of p62(DOK) tyrosine phosphorylation in macrophages. J. Biol. Chem. 274, 35855-35865.
12. Bialy L. and Waldmann H. (2005). Inhibitors of protein tyrosine phosphatases: next-generation drugs? Angew. Chem. Int. Ed. Engl. 44, 3814-3839.
13. Bittorf T., Buchse T., Sasse T., Jaster R. and Brock J. (2001). Activation of the transcription factor NF-kappaB by the erythropoietin receptor: structural requirements and biological significance. Cell. Signal. 13, 673-681.
14. Bjorbaek C., Buchholz R.M., Davis S.M., Bates S.H., Pierroz D.D., Gu H., Neel B.G., Myers M.G. Jr and Flier J.S. (2001). Divergent roles of SHP-2 in ERK activation by leptin receptors. J. Biol. Chem. 276, 4747-4755.
15. Bousquet C., Susini C. and Melmed S. (1999). Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor. J. Clin. Invest. 104, 1277-1285.
16. Bullard A.J., Govewalla P. and Yellon D.M. (2005). Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo. Basic Res. Cardiol. 100, 397-403.
17. Burks J. and Agazie Y.M. (2006). Modulation of alpha-catenin Tyr phosphorylation by SHP2 positively effects cell transformation induced by the constitutively active FGFR3. Oncogene 25, 7166-7179.
18. Cal J., Jiang W.G., Ahmed A. and Boulton M. (2006). Vascular endothelial growth factor-induced endothelial cell proliferation is regulated by interaction between VEGFR-2, SH-PTP1 and eNOS. Microvasc. Res. 71, 20-31.
19. Chan R.J. and Yoder M.C. (2004). The multiple facets of hematopoietic stem cells. Curr. Neurovasc. Res. 1, 197-206.
20. Chan R.J., Li Y., Hass M.N., Walter A., Voorhorst C.S., Shelley W.C., Yang Z., Orschell C.M. and Yoder M.C. (2006). Shp-2 heterozygous hematopoietic stem cells have deficient repopulating ability due to diminished self-renewal. Exp. Hematol. 34, 1230-1239.
21. Chauhan D., Pandey P., Hideshima T., Treon S., Raie N., Davies F.E., Shima Y., Tai Y.T., Rosen S., Avraham S., Kharbanda S. and Anderson K.C. (2000). SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. J. Biol. Chem. 275, 27845-27850.
22. Chen B., Hammonds-Odie L., Perron J., Masters B.A. and Bixby J.L. (2002). SHP-2 mediates target-regulated axonal termination and NGF-dependent neurite growth in sympathetic neurons. Dev. Biol. 252, 170-187.
23. Chen C., Edelstein L.C. and Gelinas C. (2000). The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol. Cell. Biol. 20, 2687-2695.
24. Chen J., Yu W.M., Bunting K.D. and Qu C.K. (2004). A negative role of SHP-2 tyrosine phosphatase in growth factor-dependent hematopoietic cell survival. Oncogene 23, 3659-3669.
25. Chen J., Yu W.M., Daino H., Broxmeyer H.E., Druker B.J. and Qu C.K. (2007). SHP-2 phosphatase is required for hematopoietic cell transformation by Bcr-Abl. Blood 109, 778-785.
26. Chin H., Saito T., Arai A., Yamamoto K., Kamiyama R., Miyasaka N. and Miura O. (1997). Erythropoietin and IL-3 induce tyrosine phosphorylation of CrkL and its association with Shc, SHP-2, and Cbl in hematopoietic cells. Biochem. Biophys. Res. Commun. 239, 412-417.
27. Chong Z.Z. and Maiese K. (2007). Erythropoietin employs the phosphatidylinositol 3-kinase pathway, 14-3-3, and FOXO3a nuclear trafficking to foster endothelial cell integrity. Br. J. Pharmacol. 150, 839-850.
28. Chong Z.Z., Kang J.Q. and Maiese K. (2002a). Angiogenesis and plasticity: role of erythropoietin in vascular systems. J. Hematother. Stem Cell. Res. 11, 863-871.
29. Chong Z.Z., Kang J.Q. and Maiese K. (2002b). Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation 106, 2973-2979.
30. Chong Z.Z., Kang J.Q. and Maiese K. (2002c). Hematopoietic factor erythropoietin fosters neuroprotection through novel signal transduction cascades. J. Cereb. Blood Flow Metab. 22, 503-514.
31. Chong Z.Z., Kang J.Q. and Maiese K. (2003a). Apaf-1, Bcl-xL, Cytochrome c, and Caspase-9 Form the Critical Elements for Cerebral Vascular Protection by Erythropoietin. J. Cereb. Blood Flow Metab. 23, 320-330.
32. Chong Z.Z., Kang J.Q. and Maiese K. (2003b). Erythropoietin fosters both intrinsic and extrinsic neuronal protection through modulation of microglia, Akt1, Bad, and caspase-mediated pathways. Br. J. Pharmacol. 138, 1107-1118.
33. Chong Z.Z., Kang J.Q. and Maiese K. (2003c). Metabotropic glutamate receptors promote neuronal and vascular plasticity through novel intracellular pathways. Histol. Histopathol. 18, 173-189.
34. Chong Z.Z., Lin S.H., Kang J.Q. and Maiese K. (2003d). Erythropoietin prevents early and late neuronal demise through modulation of Akt1 and induction of caspase 1, 3, and 8. J. Neurosci. Res. 71, 659-669.
35. Chong Z.Z., Lin S.H., Kang J.Q. and Maiese K. (2003e). The tyrosine phosphatase SHP2 modulates MAP kinase p38 and caspase 1 and 3 to foster neuronal survival. Cell. Mol. Neurobiol. 23, 561-578.
36. Chong Z.Z., Kang J.Q. and Maiese K. (2004a). Akt1 drives endothelial cell membrane asymmetry and microglial activation through Bcl-x(L) and caspase 1, 3, and 9. Exp. Cell. Res. 296, 196-207.
37. Chong Z.Z., Kang J.Q. and Maiese K. (2004b). Essential cellular regulatory elements of oxidative stress in early and late phases of apoptosis in the central nervous system. Antioxid. Redox. Signal. 6, 277-287.
38. Chong Z.Z., Kang J., Li F. and Maiese K. (2005a). mGluRl Targets Microglial Activation and Selectively Prevents Neuronal Cell Engulfment Through Akt and Caspase Dependent Pathways. Curr. Neurovasc. Res. 2, 197-211.
39. Chong Z.Z., Li F. and Maiese K. (2005b). Activating Akt and the brain's resources to drive cellular survival and prevent inflammatory injury. Histol. Histopathol. 20, 299-315.
40. Chong Z.Z., Li F. and Maiese K. (2005c). Erythropoietin requires NF-kappaB and its nuclear translocation to prevent early and late apoptotic neuronal injury during beta-amyloid toxicity. Curr. Neurovasc. Res. 2, 387-399.
41. Chong Z.Z., Li F. and Maiese K. (2005d). Oxidative stress in the brain: Novel cellular targets that govern survival during neurodegenerative disease. Prog. Neurobiol. 75, 207-246.
42. Chong Z.Z., Li F. and Maiese K. (2005e). Stress in the brain: novel cellular mechanisms of injury linked to Alzheimer's disease. Brain Res. Brain Res. Rev. 49, 1-21.
43. Chong Z.Z., Li F.Q. and Maiese K. (2005f). Employing new cellular therapeutic targets for Alzheimer's disease: A change for the better? Curr. Neurovasc. Res. 2, 55-72.
44. Chong Z.Z., Li F. and Maiese K. (2006a). Attempted cell cycle Induction in post-mitotic neurons occurs in early and late apoptotic programs through Rb, E2F1, and caspase 3. Curr. Neurovasc. Res. 3, 25-39.
45. Chong Z.Z., Li F. and Maiese K. (2006b). Group I metabotropic receptor neuroprotection requires Akt and its substrates that govern FOXO3a, Bim, and beta-catenin during oxidative stress. Curr. Neurovasc. Res. 3, 107-117.
46. Chong Z.Z., Li F. and Maiese K. (2007a). Cellular demise and inflammatory microglial activation during beta-amyloid toxicity are governed by Wnt1 and canonical signaling pathways. Cell. Signal. 19, 1150-1162.
47. Chong Z.Z., Li F. and Maiese K. (2007b). The pro-survival pathways of mTOR and protein kinase B target glycogen synthase kinase-3beta and nuclear factor-kappaB to foster endogenous microglial cell protection. Int. J. Mol. Med. 19, 263-272.
48. Cuevas B.D., Lu Y., Mao M., Zhang J., LaPushin R., Siminovitch K. and Mills G.B. (2001). Tyrosine phosphorylation of p85 relieves its inhibitory activity on phosphatidylinositol 3-kinase. J. Biol. Chem. 276, 27455-27461.
49. Cui T., Nakagami H., Iwai M., Takeda Y., Shiuchi T., Daviet L., Nahmias C. and Horiuchi M. (2001). Pivotal role of tyrosine phosphatase SHP-1 in AT2 receptor-mediated apoptosis in rat fetal vascular smooth muscle cell. Cardiovasc. Res. 49, 863-871.
50. Cui T.X., Nakagami H., Nahmias C., Shiuchi T., Takeda-Matsubara Y., Li J.M., Wu L., Iwai M. and Horiuchi M. (2002). Angiotensin II subtype 2 receptor activation inhibits insulin-induced phosphoinositide 3-kinase and Akt and induces apoptosis in PC12W cells. Mol. Endocrinol. 16, 2113-2123.
51. Cunnick J.M., Mei L., Doupnik C.A. and Wu J. (2001). Phosphotyrosines 627 and 659 of Gab1 constitute a bisphosphoryl tyrosine-based activation motif (BTAM) conferring binding and activation of SHP2. J. Biol. Chem. 276, 24380-24387.
52. Daigle I., Yousefi S., Colonna M., Green D.R. and Simon H.U. (2002). Death receptors bind SHP-1 and block cytokine-induced anti-apoptotic signaling in neutrophils. Nat. Med. 8, 61-67.
53. Deb T.B., Wang L., Salomon D.S., Zhou G., Dixon J.E., Gutkind J.S., Thompson S.A. and Johnson G.R. (1998). A common requirement for the catalytic activity and both SH2 domains of SHP-2 in mitogen-activated protein (MAP) kinase activation by the ErbB family of receptors. A specific role for SHP-2 in map, but not c-Jun amino-terminal kinase activation. J. Biol. Chem. 273, 16643-16646.
54. Dombroski D., Balasubramanian K. and Schroit A.J. (2000). Phosphatidylserine expression on cell surfaces promotes antibody-dependent aggregation and thrombosis in beta2-glycoprotein I-immune mice. J. Autoimmun. 14, 221-229.
55. Doonan F. and Cotter T.G. (2004). Apoptasis: A potential therapeutic target for retinal degenerations. Curr. Neurovasc. Res. 1, 41-53.
56. Du B., Ohmichi M., Takahashi K., Kawagoe J., Ohshima C., Igarashi H., Mori-Abe A., Saitoh M., Ohta T., Ohishi A., Doshida M., Tezuka N., Takahashi T. and Kurachi H. (2004). Both estrogen and raloxifene protect against beta-amyloid-induced neurotoxicity in estrogen receptor alpha-transfected PC12 cells by activation of telomerase activity via Akt cascade. J. Endocrinol. 183, 605-615.
57. Dubois M.J., Bergeron S., Kim H.J., Dombrowski L., Perreault M., Fournes B., Faure R., Olivier M., Beauchemin N., Shulman G.I., Siminovitch K.A., Kim J.K. and Marette A. (2006). The SHP-1 protein tyrosine phosphatase negatively modulates glucose homeostasis. Nat. Med. 12, 549-556.
58. Dzietko M., Felderhoff-Mueser U., Sifringer M., Krutz B., Bittigau P., Thor F., Heumann R., Buhrer C., Ikonomidou C. and Hansen H.H. (2004). Erythropoietin protects the developing brain against N-methyl-D-aspartate receptor antagonist neurotoxicity. Neurobiol. Dis. 15, 177-187.
59. Easton J.B., Royer A.R. and Middlemas D.S. (2006). The protein tyrosine phosphatase, Shp2, is required for the complete activation of the RAS/ MAPK pathway by brain-derived neurotrophic factor. J. Neurochem. 97, 834-845.
60. Esposito G., De Filippis D., Maiuri M.C., De Stefano D., Carnuccio R. and Iuvone T. (2006). Gannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-kappaB involvement. Neurosci. Lett. 399, 91-95.
61. Feng G.S., Shen R., Heng H.H., Tsui LC., Kazlauskas A. and Pawson T. (1994). Receptor-binding, tyrosine phosphorylation and chromosome localization of the mouse SH2-containing phosphotyrosine phosphatase Syp. Oncogene 9, 1545-1550.
62. Ferrajoli A., Faderl S., Ravandi F. and Estrov Z. (2006). The JAK-STAT pathway: a therapeutic target in hematological malignancies. Curr. Cancer Drug Targets 6, 671-679.
63. Ferretti P. (2004). Neural stem cell plasticity: Recruitment of endogenous populations for regeneration. Curr. Neurovasc. Res. 1, 215-229.
64. Forget G., Gregory D.J., Whitcombe L.A. and Olivier M. (2006). Role of host protein tyrosine phosphatase SHP-1 in Leishmania donovani-induced inhibition of nitric oxide production. Infect. Immun. 74, 6272-6279.
65. Forget G., Matte C., Siminovitch K.A., Rivest S., Pouliot P. and Olivier M. (2005). Regulation of the Leishmania-induced innate inflammatory response by the protein tyrosine phosphatase SHP-1. Eur. J. Immunol. 35, 1906-1917.
66. Fukunaga K., Noguchi T., Takeda H., Matozaki T., Hayashi Y., Itoh H. and Kasuga M. (2000). Requirement for protein-tyrosine phosphatase SHP-2 in insulin-induced activation of c-Jun NH(2)-terminal kinase. J. Biol. Chem. 275, 5208-5213.
67. Furukawa T., Narita M., Sakaue M., Otsuka T., Kuroha T., Masuko M., Azegami T., Kishi K., Takahashi M., Utsumi J., Koike T. and Aizawa Y. (1997). Primary familial polycythaemia associated with a novel point mutation in the erythropoietin receptor. Br. J. Haematol. 99, 222-227.
68. Genc S., Koroglu T.F. and Genc K. (2004). Erythropoietin and the nervous system. Brain Res. 1000, 19-31.
69. Godeny M.D., Sayyah J., Vonderlinden D., Johns M., Ostrov D.A., Caldwell-Busby J. and Sayeski P.P. (2006). The N-terminal SH2 domain of the tyrosine phosphatase, SHP-2, is essential for Jak2-dependent signaling via the angiotensin II type AT(1) receptor. Cell. Signal.
70. Greco A. and Minghetti L. (2004). Isoprostanes as biomarkers and mediators of oxidative injury in infant and adult central nervous system diseases. Curr. Neurovasc. Res. 1, 341-354.
71. Grimaldi C.M., Cleary J., Dagtas A.S., Moussai D. and Diamond B. (2002). Estrogen alters thresholds for B cell apoptosis and activation. J. Clin. Invest. 109, 1625-1633.
72. Grote K., Luchtefeld M. and Schieffer B. (2005). JANUS under stress-role of JAK/STAT signaling pathway in vascular diseases. Vascul. Pharmacol. 43, 357-363.
73. Guo G. and Bhat N.R. (2006). Hypoxia/Reoxygenation Differentially Modulates NF-kappaB Activation and iNOS Expression in Astrocytes and Microglia. Antioxid. Redox Signal. 8, 911-918.
74. Haddad J.J. (2004). Mitogen-activated protein kinases and the evolution of Alzheimer's: a revolutionary neurogenetic axis for therapeutic intervention? Prog. Neurobiol. 73, 359-377.
75. Haider U.G., Roos T.U., Kontaridis M.I., Neel B.G., Sorescu D., Griendling K.K., Vollmar A.M. and Dirsch V.M. (2005). Resveratrol inhibits angiotensin II- and epidermal growth factor-mediated Akt activation: role at Gab1 and Shp2. Mol. Pharmacol. 68, 41-48.
76. Hakak Y., Hsu Y.S. and Martin G.S. (2000). Shp-2 mediates v-Src-induced morphological changes and activation of the anti-apoptotic protein kinase Akt. Oncogene 19, 3164-3171.
77. Hardee M.E., Rabbani Z.N., Arcasoy M.O., Kirkpatrick J.P., Vujaskovic Z., Dewhirst M.W. and Blackwell K.L. (2006). Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity. Mol. Cancer Ther. 5, 356-361.
78. Hayden M.S. and Ghosh S. (2004). Signaling to NF-kappaB. Genes Dev. 18, 2195-2224.
79. Herrera Abreu M.T., Wang Q., Vachon E., Suzuki T., Chow C.W., Wang Y., Hong O., Villar J., McCulloch C.A. and Downey G.P. (2006). Tyrosine phosphatase SHP-2 regulates IL-1 signaling in fibroblasts through focal adhesions. J. Cell. Physiol. 207, 132-143.
80. Hoffmann P.R., deCathelineau A.M., Ogden C.A., Leverrier Y., Bratton D.L., Daleke D.L., Ridley A.J., Fadok V.A. and Henson P.M. (2001). Phosphatidylserine (PS) induces PS receptor-mediated macropinocytosis and promotes clearance of apoptotic cells. J. Cell Biol. 155, 649-659.
81. Holgado-Madruga M. and Wong A.J. (2003). Gab1 is an integrator of cell death versus cell survival signals in oxidative stress. Mol. Cell. Biol. 23, 4471-4484.
82. Hong J.R., Lin G.H., Lin C.J., Wang W.P., Lee C.C., Lin T.L. and Wu J.L. (2004). Phosphatidylserine receptor is required for the engulfment of dead apoptotic cells and for normal embryonic development in zebrafish. Development 131, 5417-5427.
83. Horvat A., Schwaiger F., Hager G., Brocker F., Streif R., Knyazev P., Ullrich A. and Kreutzberg G.W. (2001). A novel role for protein tyrosine phosphatase shp1 in controlling glial activation in the normal and injured nervous system. J. Neurosci. 21, 865-874.
84. Ivins Zito C., Kontaridis M.I., Fornaro M., Feng G.S. and Bennett A.M. (2004). SHP-2 regulates the phosphatidylinositide 3′-kinase/Akt pathway and suppresses caspase 3-mediated apoptosis. J. Cell. Physiol. 199, 227-236.
85. Jacobsen E.A., Ananieva O., Brown M.L. and Chang Y. (2006). Growth, differentiation, and malignant transformation of pre-B cells mediated by inducible activation of v-Abl oncogene. J. Immunol. 176, 6831-6838.
86. Jessel R., Haertel S., Socaciu C., Tykhonova S. and Diehl H.A. (2002). Kinetics of apoptotic markers in exogeneously induced apoptosis of EL4 cells. J. Cell. Mol. Med. 6, 82-92.
87. Jiao H., Berrada K., Yang W., Tabrizi M., Platanias L.C. and Yi T. (1996). Direct association with and dephosphorylation of Jak2 kinase by the SH2- domain-containing protein tyrosine phosphatase SHP-1. Mol. Cell. Biol. 16, 6985-6992.
88. Kang J.Q., Chong Z.Z. and Maiese K. (2003a). Akt1 protects against inflammatory microglial activation through maintenance of membrane asymmetry and modulation of cysteine protease activity. J. Neurosci. Res. 74, 37-51.
89. Kang J.Q., Chong Z.Z. and Maiese K. (2003b). Critical role for Akt1 in the modulation of apoptotic phosphatidylserine exposure and microglial activation. Mol. Pharmacol. 64, 557-569.
90. Kapoor G.S., Zhan Y., Johnson G.R. and O'Rourke D.M. (2004). Distinct domains in the SHP-2 phosphatase differentially regulate epidermal growth factor receptor/NF-kappaB activation through Gab1 in glioblastoma cells. Mol. Cell. Biol. 24, 823-836.
91. Kawakami M., Sekiguchi M., Sato K., Kozaki S. and Takahashi M. (2001). Erythropoietin receptor-mediated inhibition of exocytotic glutamate release confers neuroprotection during chemical ischemia. J. Biol. Chem. 276, 39469-39475.
92. Ke Y., Lesperance J., Zhang E.E., Bard-Chapeau E.A., Oshima R.G., Muller W.J. and Feng G.S. (2006). Conditional deletion of Shp2 in the mammary gland leads to impaired lobulo-alveolar outgrowth and attenuated Stat5 activation. J. Biol. Chem. 281, 34374-34380.
93. Kellerer M., Lammers R., Fritsche A., Strack V., Machicao F., Borboni P., Ullrich A. and Haring H.U. (2001). Insulin inhibits leptin receptor signalling in HEK293 cells at the level of janus kinase-2: a potential mechanism for hyperinsulinaemia-associated leptin resistance. Diabetologia 44, 1125-1132.
94. Kim C.H., Qu C.K., Hangoc G., Cooper S., Anzai N., Feng G.S. and Broxmeyer H.E. (1999). Abnormal chemokine-induced responses of immature and mature hematopoietic cells from motheaten mice implicate the protein tyrosine phosphatase SHP-1 in chemokine responses. J. Exp. Med. 190, 681-690.
95. Kim H.Y., Park S.J., Joe E.H. and Jou I. (2006). Raft-mediated Src homology 2 domain-containing proteintyrosine phosphatase 2 (SHP-2) regulation in microglia. J. Biol. Chem. 281, 11872-11878.
96. Klingmuller U., Lorenz U., Cantley L.C., Neel B.G. and Lodish H.F. (1995). Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 80, 729-738.
97. Koyama R. and Ikegaya Y. (2004). Mossy fiber sprouting as a potential therapeutic target for epilepsy. Curr. Neurovasc. Res. 1, 3-10.
98. Krotz F., Engelbrecht B., Buerkle M.A., Bassermann F., Bridell H., Gloe T., Duyster J., Pohl U. and Sohn H.Y. (2005). The tyrosine phosphatase, SHP-1, is a negative regulator of endothelial superoxide formation. J. Am. Coll. Cardiol. 45, 1700-1706.
99. Kwon M., Ling Y., Maile L.A., Badley-Clark J. and Clemmons D.R. (2006). Recruitment of the tyrosine phosphatase Src homology 2 domain tyrosine phosphatase-2 to the p85 subunit of phosphatidylinositol-3 (PI-3) kinase is required for insulin-like growth factor-I-dependent PI-3 kinase activation in smooth muscle cells. Endocrinology 147, 1458-1465.
100. Laramee M., Chabot C., Cloutier M., Stenne R., Holgado-Madruga M., Wong A.J. and Royal I. (2007). The scaffolding adapter Gab1 mediates VEGF signaling and is required for endothelial cell migration and capillary formation. J. Biol. Chem. 282, 7758-7769.
101. Lee S.R., Kwon K.S., Kim S.R. and Rhee S.G. (1998). Reversible inactivation of protein-tyrosine phosphatase 1B in A431 cells stimulated with epidermal growth factor. J. Biol. Chem. 273, 15366-15372.
102. Li F., Chong Z.Z. and Maiese K. (2004). Erythropoietin on a tightrope: Balancing neuronal and vascular protection between intrinsic and extrinsic pathways. Neurosignals 13, 265-289.
103. Li F., Chong Z.Z. and Maiese K. (2005). Vital elements of the wnt-frizzled signaling pathway in the nervous system. Curr. Neurovasc. Res. 2, 331-340.
104. Li F., Chong Z.Z. and Maiese K. (2006a). Cell Life Versus Cell Longevity: The Mysteries Surrounding the NAD(+) Precursor Nicotinamide. Curr. Med. Chem. 13, 883-895.
105. Li F., Chong Z.Z. and Maiese K. (2006b). Microglial integrity is maintained by erythropoietin through integration of Akt and its substrates of glycogen synthase kinase-3beta, beta-catenin, and nuclear factor-kappaB. Curr. Neurovasc. Res. 3, 187-201.
106. Li F., Chong Z.Z. and Maiese K. (2006c). Winding through the WNT pathway during cellular development and demise. Histol. Histopathol. 21, 103-124.
107. Lin S.H., Chong Z.Z. and Maiese K. (2001). Nicotinamide: A nutritional supplement that provides protection against neuronal and vascular injury. J. Med. Food 4, 27-38.
108. Lin S.H., Vincent A., Shaw T., Maynard K.I. and Maiese K. (2000). Prevention of nitric oxide-induced neuronal injury through the modulation of independent pathways of programmed cell death. J. Cereb. Blood Flow Metab. 20, 1380-1391.
109. Liu D., Martino G., Thangaraju M., Sharma M., Halwani F., Shen S.H., Patel Y.C. and Srikant C.B. (2000). Caspase-8-mediated intracellular acidification precedes mitochondrial dysfunction in somatostatin-induced apoptosis. J. Biol. Chem. 275, 9244-9250.
110. Lu Y., Yu Q., Liu J.H., Zhang J., Wang H., Koul D., McMurray J.S., Fang X., Yung W.K., Siminovitch K.A. and Mills G.B. (2003). Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. J. Biol. Chem. 278, 40057-40066.
111. Lurie D.I., Solca F., Fischer E.H. and Rubel E.W. (2000). Tyrosine phosphatase SHP-1 immunoreactivity increases in a subset of astrocytes following deafferentation of the chicken auditory brainstem. J. Comp. Neurol. 421, 199-214.
112. Lyons B.L., Smith R.S., Hurd R.E., Hawes N.L., Burzenski L.M., Nusinowitz S., Hasham M.G., Chang B. and Shultz L.D. (2006). Deficiency of SHP-1 protein-tyrosine phosphatase in "viable motheaten" mice results in retinal degeneration. Invest. Ophthalmol. Vis. Sci. 47, 1201-1209.
113. Maas M., Wang R., Paddock C., Kotamraju S., Kalyanaraman B., Newman P.J. and Newman D.K. (2003). Reactive oxygen species induce reversible PECAM-1 tyrosine phosphorylation and SHP-2 binding. Am. J. Physiol. Heart Circ. Physiol. 285, H2336-2344.
114. Maiese K. (2002). Organic brain disease. In: Encyclopedia of the human brain. 1st Edition. V.S. Ramachandran (ed). Elsevier Science. pp 509-527.
115. Maiese K. and Chong Z.Z. (2003). Nicotinamide: necessary nutrient emerges as a novel cytoprotectant for the brain. Trends Pharmacol. Sci. 24, 228-232.
116. Maiese K. and Chong Z.Z. (2004). Insights into oxidative stress and potential novel therapeutic targets for Alzheimer disease. Restor. Neurol. Neurosci. 22, 87-104.
117. Maiese K. and Vincent A.M. (2000a). Critical temporal modulation of neuronal programmed cell injury. Cell. Mol. Neurobiol. 20, 383-400.
118. Maiese K. and Vincent A.M. (2000b). Membrane asymmetry and DNA degradation: functionally distinct determinants of neuronal programmed cell death. J. Neurosci. Res. 59, 568-580.
119. Maiese K., Ahmad I., TenBroeke M. and Gallant J. (1999). Metabotropic glutamate receptor subtypes independently modulate neuronal intracellular calcium. J. Neurosci. Res. 55, 472-485.
120. Maiese K., Li F. and Chong Z.Z. (2004). Erythropoietin in the brain: can the promise to protect be fulfilled? Trends Pharmacol. Sci. 25, 577-583.
121. Maiese K., Chong Z.Z. and Li F. (2005a). Driving cellular plasticity and survival through the signal transduction pathways of metabotropic glutamate receptors. Curr. Neurovasc. Res. 2, 425-446.
122. Maiese K., Li F. and Chong Z.Z. (2005b). Erythropoietin and cancer. JAMA 293, 1858-1859.
123. Maiese K., Li F. and Chong Z.Z. (2005c). New avenues of exploration for erythropoietin. JAMA 293, 90-95.
124. Maiese K., Morhan S.D. and Chong Z.Z. (2007). Oxidative stress biology and cell injury during type 1 and type 2 diabetes mellitus. Curr. Neurovasc. Res. 4, 63-71.
125. Mallat M., Marin-Teva J.L. and Cheret C. (2005). Phagocytosis in the developing CNS: more than clearing the corpses. Curr. Opin. Neurobiol. 15, 101-107.
126. Mari C., Karabiyikoglu M., Goris M.L., Tait J.F., Yenari M.A. and Blankenberg F.G. (2004). Detection of focal hypoxic-ischemic injury and neuronal stress in a rodent model of unilateral MCA occlusion/ reperfusion using radiolabeled annexin V. Eur. J. Nucl. Med. Mol. Imaging 31, 733-739.
127. Marrero M.B., Venema V.J., Ju H., Eaton D.C. and Venema R.C. (1998). Regulation of angiotensin II-induced JAK2 tyrosine phosphorylation: roles of SHP-1 and SHP-2. Am. J. Physiol. 275, C1216-1223.
128. Marsh H.N., Dubreuil C.I., Quevedo C., Lee A., Majdan M., Walsh G.S., Hausdorff S., Said F.A., Zoueva O., Kozlowski M., Siminovitch K., Neel B.G., Miller F.D. and Kaplan D.R. (2003). SHP-1 negatively regulates neuronal survival by functioning as a TrkA phosphatase. J. Cell. Biol. 163, 999-1010.
129. Massa P.T. and Wu C. (1996). The role of protein tyrosine phosphatase SHP-1 in the regulation of IFN-gamma signaling in neural cells. J. Immunol. 157, 5139-5144.
130. Massa P.T. and Wu C. (1998). Increased inducible activation of NF-kappaB and responsive genes in astrocytes deficient in the protein tyrosine phosphatase SHP-1. J. Interferon Cytokine Res. 18, 499-507.
131. Massa P.T., Saha S., Wu C. and Jarosinski K.W. (2000). Expression and function of the protein tyrosine phosphatase SHP-1 in oligodendrocytes. Glia 29, 376-385.
132. Massa P.T., Wu C. and Fecenko-Tacka K. (2004). Dysmyelination and reduced myelin basic protein gene expression by oligodendrocytes of SHP-1-deficient mice. J. Neurosci. Res. 77, 15-25.
133. Matsubara H., Shibasaki Y., Okigaki M., Mori Y., Masaki H., Kosaki A., Tsutsumi Y., Uchiyama V., Fujiyama S., Nose A., Iba O., Tateishi E., Hasegawa T., Horiuchi M., Nahmias C. and Iwasaka T. (2001). Effect of angiotensin II type 2 receptor on tyrosine kinase Pyk2 and c-Jun NH2-terminal kinase via SHP-1 tyrosine phosphatase activity: evidence from vascular-targeted transgenic mice of AT2 receptor. Biochem. Biophys. Res. Commun. 282, 1085-1091.
134. Mattoon D.R., Lamothe B., Lax I. and Schlessinger J. (2004). The docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3K/Akt cell survival pathway. BMC Biol. 2, 24.
135. Mehlhorn G., Hollborn M. and Schliebs R. (2000). Induction of cytokines in glial cells surrounding cortical beta-amyloid plaques in transgenic Tg2576 mice with Alzheimer pathology. Int. J. Dev. Neurosci. 18, 423-431.
136. Mena-Duran A.V., Togo S.H., Bazhenova L., Cervera J., Bethel K., Senent M.L., Nieva J., Sanz G.F., Sanz M.A., Saven A. and Mustelin T. (2005). SHP1 expression in bone marrow biopsies of myelodysplastic syndrome patients: a new prognostic factor. Br. J. Haematol. 129, 791-794.
137. Menon M.P., Fang J. and Wojchowski D.M. (2006a). Core erythropoietin receptor signals for late erythroblast development. Blood 107, 2662-2672.
138. Menon M.P., Karur V., Bogacheva O., Bogachev O., Cuetara B. and Wojchowski D.M. (2006b). Signals for stress erythropoiesis are integrated via an erythropoietin receptor-phosphotyrosine-343-Stat5 axis. J. Clin. Invest. 116, 683-694.
139. Miki T., Miura T., Yano T., Takahashi A., Sakamoto J., Tanno M., Kobayashi H., Ikeda V., Nishihara M., Naitoh K., Ohori K. and Shimamoto K. (2006). Alteration in erythropoietin-induced cardioprotective signaling by postinfarct ventricular remodeling. J. Pharmacol. Exp. Ther. 317, 68-75.
140. Milarski K.L. and Saltiel A.R. (1994). Expression of catalytically inactive Syp phosphatase in 3T3 cells blocks stimulation of mitogen-activated protein kinase by insulin. J. Biol. Chem. 269, 21239-21243.
141. Minoo P., Zadeh M.M., Rottapel R., Lebrun J.J. and Ali S. (2004). A novel SHP-1/Grb2-dependent mechanism of negative regulation of cytokine-receptor signaling: contribution of SHP-1 C-terminal tyrosines in cytokine signaling. Blood 103, 1398-1407.
142. Mizuno K., Tagawa Y., Watanabe N., Ogimoto M. and Yakura H. (2005). SLP-76 is recruited to CD22 and dephosphorylated by SHP-1, thereby regulating B cell receptor-induced c-Jun N-terminal kinase activation. Eur. J. lmmunol. 35, 644-654.
143. Motohashi T., Nakamura Y., Osawa M., Hiroyama T., Iwama A., Shibuya A. and Nakauchi H. (2001). Increased cell surface expression of C-terminal truncated erythropoietin receptors in polycythemia. Eur. J. Haematol. 67, 88-93.
144. Nakagami Y., Nishimura S., Murasugi T., Kubo T., Kaneko I., Meguro M., Marumoto S., Kogen H., Koyama K. and Oda T. (2002). A novel compound RS-0466 reverses beta-amyloid-induced cytotoxicity through the Akt signaling pathway in vitro. Eur. J. Pharmacol. 457, 11-17.
145. Nakata S., Matsumura I., Tanaka H., Ezoe S., Satoh Y., Ishikawa J., Era T. and Kanakura Y. (2004). NF-kappaB family proteins participate in multiple steps of hematopoiesis through elimination of reactive oxygen species. J. Biol. Chem. 279, 55578-55586.
146. Nakatani K., Sakaue H., Thompson D.A., Weigel R.J. and Roth R.A. (1999). Identification of a human Akt3 (protein kinase B gamma) which contains the regulatory serine phosphorylation site. Biochem. Biophys. Res. Commun. 257, 906-910.
147. Nishihara M., Miura T., Miki T., Sakamoto J., Tanno M., Kobayashi H., Ikeda Y., Ohori K., Takahashi A. and Shimamoto K. (2006). Erythropoietin affords additional cardioprotection to preconditioned hearts by enhanced phosphorylation of glycogen synthase kinase-3 beta. Am. J. Physiol. Heart Circ. Physiol. 291, H748-755.
148. Owada Y., Utsunomiya A., Yoshimoto T. and Kondo H. (1997). Expression of mRNA for Akt, serine-threonine protein kinase, in the brain during development and its transient enhancement following axotomy of hypoglossal nerve. J. Mol. Neurosci. 9, 27-33.
149. Paling N.R. and Welham M.J. (2002). Role of the protein tyrosine phosphatase SHP-1 (Src homology phosphatase-1) in the regulation of interleukin-3-induced survival, proliferation and signalling. Biochem. J. 368, 885-894.
150. Paling N.R. and Welham M.J. (2005). Tyrosine phosphatase SHP-1 acts at different stages of development to regulate hematopoiesis. Blood 105, 4290-4297.
151. Pani G., Kozlowski M., Cambier J.C., Mills G.B. and Siminovitch K.A. (1995). Identification of the tyrosine phosphatase PTP1C as a B cell antigen receptor-associated protein involved in the regulation of B cell signaling. J. Exp. Med. 181, 2077-2084.
152. Parsa C.J., Matsumoto A., Kim J., Riel R.U., Pascal L.S., Walton G.B., Thompson R.B., Petrofski J.A., Annex B.H., Stamler J.S. and Koch W.J. (2003). A novel protective effect of erythropoietin in the infarcted heart. J. Clin. Invest. 112, 999-1007.
153. Pazdrak K., Adachi T. and Alam R. (1997). Src homology 2 protein tyrosine phosphatase (SHPTP2)/Src homology 2 phosphatase 2 (SHP2) tyrosine phosphatase is a positive regulator of the interleukin 5 receptor signal transduction pathways leading to the prolongation of eosinophil survival. J. Exp. Med. 186, 561-568.
154. Pluskota E., Chen Y. and D'Souza S.E. (2000). Src homology domain 2-containing tyrosine phosphatase 2 associates with intercellular adhesion molecule 1 to regulate cell survival. J. Biol. Chem. 275, 30029-30036.
155. Qu C.K. and Feng G.S. (1998). Shp-2 has a positive regulatory role in ES cell differentiation and proliferation. Oncogene 17, 433-439.
156. Rakesh K. and Agrawal D.K. (2005). Controlling cytokine signaling by constitutive inhibitors. Biochem. Pharmacol. 70, 649-657.
157. Ruhul Amin A.R., Oo M.L., Senga T., Suzuki N., Feng G.S. and Hamaguchi M. (2003). SH2 domain containing protein tyrosine phosphatase 2 regulates concanavalin A-dependent secretion and activation of matrix metalloproteinase 2 via the extracellular signal-regulated kinase and p38 pathways. Cancer Res. 63, 6334-6339.
158. Rusanescu G., Yang W., Bai A., Neel B.G. and Feig L.A. (2005). Tyrosine phosphatase SHP-2 is a mediator of activity-dependent neuronal excitotoxicity. EMBO J. 24, 305-314.
159. Sae-Ung N., Matsushima T., Choi I., Abe Y., Winichagoon P., Fucharoen S., Nawata H. and Muta K. (2005). Role of NF-kappa B in regulation of apoptosis of erythroid progenitor cells. Eur. J. Haematol. 74, 315-323.
160. Sankarapandi S., Zweier J.L., Mukherjee G., Quinn M.T. and Huso D.L. (1998). Measurement and characterization of superoxide generation in microglial cells: evidence for an NADPH oxidase-dependent pathway. Arch. Biochem. Biophys. 353, 312-321.
161. Sanz O., Acarin L., Gonzalez B. and Castellano B. (2002). NF-kappaB and IkappaBalpha expression following traumatic brain injury to the immature rat brain. J. Neurosci. Res. 67, 772-780.
162. Schaapveld R., Wieringa B. and Hendriks W. (1997). Receptor-like protein tyrosine phosphatases: alike and yet so different. Mol. Biol. Rep. 24, 247-262.
163. Seki N., Hashimoto N., Suzuki Y., Mori S., Amano K. and Saito Y. (2002). Role of SRC homology 2-containing tyrosine phosphatase 2 on proliferation of rat smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 22, 1081-1085.
164. Servidei T., Bhide P.G., Huang Z., Moskowitz M.A., Harsh G. and Reeves S.A. (1998). The protein tyrosine phosphatase SHP-2 is expressed in glial and neuronal progenitor cells, postmitotic neurons and reactive astrocytes. Neuroscience 82, 529-543.
165. Sharples E.J., Thiemermann C. and Yaqoob M.M. (2005). Mechanisms of disease: Cell death in acute renal failure and emerging evidence for a protective role of erythropoietin. Nat. Clin. Pract. Nephrol. 1, 87-97.
166. Shi Z.Q., Lu W. and Feng G.S. (1998). The Shp-2 tyrosine phosphatase has opposite effects in mediating the activation of extracellular signal-regulated and c-Jun NH2-terminal mitogen-activated protein kinases. J. Biol. Chem. 273, 4904-4908.
167. Siu A.W. and To C.H. (2002). Nitric oxide and hydroxyl radical-induced retinal lipid peroxidation in vitro. Clin. Exp. Optom. 85, 378-382.
168. Staal S.P. (1987). Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc. Natl. Acad. Sci. USA 84, 5034-5037.
169. Staal S.P., Huebner K., Croce C.M., Parsa N.Z. and Testa J.R. (1988). The AKT1 proto-oncogene maps to human chromosome 14, band q32. Genomics 2, 96-98.
170. Stoker A.W. (2005). Protein tyrosine phosphatases and signalling. J. Endocrinol. 185, 19-33.
171. Sugano M., Tsuchida K., Hata T. and Makino N. (2005). RNA interference targeting SHP-1 attenuates myocardial infarction in rats. FASEB J. 19, 2054-2056.
172. Sun X.M. and Cohen G.M. (1994). Mg(2+)-dependent cleavage of DNA into kilobase pair fragments is responsible for the initial degradation of DNA in apoptosis. J. Biol. Chem. 269, 14857-14860.
173. Suzuki T., Matozaki T., Mizoguchi A. and Kasuga M. (1995). Localization and subcellular distribution of SH-PTP2, a protein-tyrosine phosphatase with Src homology-2 domains, in rat brain. Biochem. Biophys. Res. Commun. 211, 950-959.
174. Takai S., Yamada M., Araki T., Koshimizu H., Nawa H. and Hatanaka H. (2002). Shp-2 positively regulates brain-derived neurotrophic factor-promoted survival of cultured ventral mesencephalic dopaminergic neurons through a brain immunoglobulin-like molecule with tyrosine-based activation motifs/Shp substrate-1. J. Neurochem. 82, 353-364.
175. Torriglia A., Chaudun E., Courtois Y. and Counis M.F. (1997). On the use of Zn2+ to discriminate endonucleases activated during apoptosis. Biochimie 79, 435-438.
176. Touyz R,M. (2004). Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? Hypertension 44, 248-252.
177. Um M. and Lodish H.F. (2006). Antiapoptotic Effects of Erythropoietin in Differentiated Neuroblastoma SH-SY5Y Cells Require Activation of Both the STAT5 and AKT Signaling Pathways. J. Biol. Chem. 281, 5648-5656.
178. Valencia A.M., Oliva J.L., Bodega G., Chiloeches A., Lopez-Ruiz P., Prieto J.C., Susini C. and Colas B. (1997). Identification of a protein-tyrosine phosphatase (SHP1) different from that associated with acid phosphatase in rat prostate. FEBS Lett. 406, 42-48.
179. Vantler M., Huntgeburth M., Caglayan E., Ten Freyhaus H., Schnabel P. and Rosenkranz S. (2006). PI3-kinase/Akt-dependent antiapoptotic signaling by the PDGF alpha receptor is negatively regulated by Src family kinases. FEBS Lett. 580, 6769-6776.
180. Vincent A.M. and Maiese K. (1999). Nitric oxide induction of neuronal endonuclease activity in programmed cell death. Exp. Cell. Res. 246, 290-300.
181. Vincent A.M., TenBroeke M. and Maiese K. (1999). Metabotropic glutamate receptors prevent programmed cell death through the modulation of neuronal endonuclease activity and intracellular pH. Exp. Neurol. 155, 79-94.
182. Wadley G.D., Konstantopaulos N., Macaulay L., Howlett K., Garnham A., Hargreaves M. and Cameron-Smith D. (2007). Increased insulin-stimulated Akt pSer473 and cytosolic SHP2 protein abundance in human skeletal muscle following acute exercise and short-term training. J. Appl. Physiol. 102, 1624-1631.
183. Wang H. and MacNaughton W.K. (2005). Overexpressed beta-catenin blocks nitric oxide-induced apoptosis in colonic cancer cells. Cancer Res. 65, 8604-8607.
184. Wang J.F., Zhang X. and Groopman J.E. (2004). Activation of vascular endothelial growth factor receptor-3 and its downstream signaling promote cell survival under oxidative stress. J. Biol. Chem. 279, 27088-27097.
185. Wang J.Y., Shum A.Y. and Ho Y.J. (2003). Oxidative neurotoxicity in rat cerebral cortex neurons: synergistic effects of H2O2 and NO on apoptosis involving activation of p38 mitogen-activated protein kinase and caspase-3. J. Neurosci. Res. 72, 508-519.
186. Wang N., Li Z., Ding R., Frank G.D., Senbonmatsu T., Landon E.J., Inagami T. and Zhao Z.J. (2006). Antagonism or synergism. Role of tyrosine phosphatases SHP-1 and SHP-2 in growth factor signaling. J. Biol. Chem. 281, 21878-21883.
187. Weber J.T. (2004). Calcium homeostasis following traumatic neuronal injury. Curr. Neurovasc. Res. 1, 151-171.
188. Wheadon H., Edmead C. and Welham M.J. (2003). Regulation of interleukin-3-induced substrate phosphorylation and cell survival by SHP-2 (Src-homology protein tyrosine phosphatase 2). Biochem. J. 376, 147-157.
189. White D.W. and Tartaglia L.A. (1996). Leptin and OB-R: body weight regulation by a cytokine receptor. Cytokine Growth Factor Rev. 7, 303-309.
190. Wickrema A., Chen F., Namin F., Yi T., Ahmad S., Uddin S., Chen Y.H., Feldman L., Stock W., Hoffman R. and Platanias L.C. (1999a). Defective expression of the SHP-1 phosphatase in polycythemia vera. Exp. Hematol. 27, 1124-1132.
191. Wickrema A., Uddin S., Sharma A., Chen F., Alsayed Y., Ahmad S., Sawyer S.T., Krystal G., Yi T., Nishada K., Hibi M., Hirano T. and Platanias L.C. (1999b). Engagement of Gab1 and Gab2 in erythropoietin signaling. J. Biol. Chem. 274, 24469-24474.
192. Wilks A.F., Harpur A.G., Kurban R.R., Ralph S.J., Zurcher G. and Ziemiecki A. (1991). Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase. Mol. Cell. Biol. 11, 2057-2065.
193. Wu D.W., Stark K.C., Dunnington D., Dillon S.B., Yi T., Jones C. and Pelus L.M. (2000). SH2-Containing protein tyrosine phosphatase-1 (SHP-1) association with Jak2 in UT-7/Epo cells. Blood Cells Mol. Dis. 26, 15-24.
194. Wu L., Iwai M., Li Z., Shiuchi T., Min L.J., Cui T.X., Li J.M., Okumura M., Nahmias C. and Horiuchi M. (2004). Regulation of inhibitory protein-kappaB and monocyte chemoattractant protein-1 by angiotensin II type 2 receptor-activated Src homology protein tyrosine phosphatase-1 in fetal vascular smooth muscle cells. Mol. Endocrinol. 18, 666-678.
195. Xie Z.H., Zhang J. and Siraganian R.P. (2000). Positive regulation of c-Jun N-terminal kinase and TNF-alpha production but not histamine release by SHP-1 in RBL-2H3 mast cells. J. Immunol. 164, 1521-1528.
196. Yamamoto T., Maruyama W., Kato Y., Yi H., Shamoto-Nagai M., Tanaka M., Sato Y. and Naoi M. (2002). Selective nitration of mitochondrial complex I by peroxynitrite: involvement in mitochondria dysfunction and cell death of dopaminergic SH-SY5Y cells. J. Neural Transm. 109, 1-13.
197. Yamao T., Noguchi T., Takeuchi O., Nishiyama U., Morita H., Hagiwara T., Akahori H., Kato T., Inagaki K., Okazawa H., Hayashi Y., Matozaki T., Takeda K., Akira S. and Kasuga M. (2002). Negative regulation of platelet clearance and of the macrophage phagocytic response by the transmembrane glycoprotein SHPS-1. J. Biol. Chem. 277, 39833-39839.
198. Yamauchi K., Milarski K.L., Saltiel A.R. and Pessin J.E. (1995). Protein-tyrosine-phosphatase SHPTP2 is a required positive effector for insulin downstream signaling. Proc. Natl. Acad. Sci. USA 92, 664-668.
199. Yang W., Klaman L.D., Chen B., Araki T., Harada H., Thomas S.M., George E.L. and Neel B.G. (2006). An Shp2/SFK/Ras/Erk signaling pathway controls trophoblast stem cell survival. Dev. Cell. 10, 317-327.
200. Yi T., Mui A.L., Krystal G. and Ihle J.N. (1993). Hematopoietic cell phosphatase associates with the interleukin-3 (IL-3) receptor beta chain and down-regulates IL-3-induced tyrosine phosphorylation and mitogenesis. Mol. Cell. Biol. 13, 7577-7586.
201. Yi T., Zhang J., Miura O. and Ihle J.N. (1995). Hematopoietic cell phosphatase associates with erythropoietin (Epo) receptor after Epo-induced receptor tyrosine phosphorylation: identification of potential binding sites. Blood 85, 87-95.
202. Yi T.L., Cleveland J.L. and Ihle J.N. (1992). Protein tyrosine phosphatase containing SH2 domains: characterization, preferential expression in hematopoietic cells, and localization to human chromosome 12p12-p13. Mol. Cell. Biol. 12, 836-846.
203. You M. and Zhao Z. (1997). Positive effects of SH2 domain-containing tyrosine phosphatase SHP-1 on epidermal growth factor- and interferon-gamma-stimulated activation of STAT transcription factors in HeLa cells. J. Biol. Chem. 272, 23376-23381.
204. You M., Flick L.M., Yu D. and Feng G.S. (2001). Modulation of the nuclear factor kappa B pathway by Shp-2 tyrosine phosphatase in mediating the induction of interleukin (IL)-6 by IL-1 or tumor necrosis factor. J. Exp. Med. 193, 101-110.
205. You M., Yu D.H. and Feng G.S. (1999). Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway. Mol. Cell. Biol. 19, 2416-2424.
206. Yu C.L., Jin Y.J. and Burakoff S.J. (2000). Cytosolic tyrosine dephosphorylation of STAT5. Potential role of SHP-2 in STAT5 regulation. J. Biol. Chem. 275, 599-604.
207. Yu W.M., Hawley T.S., Hawley R.G. and Qu C.K. (2003). Catalytic-dependent and -independent roles of SHP-2 tyrosine phosphatase in interleukin-3 signaling. Oncogene 22, 5995-6004.
208. Yu Z., Su L., Hoglinger O., Jaramillo M.L, Banville D. and Shen S.H. (1998). SHP-1 associates with both platelet-derived growth factor receptor and the p85 subunit of phosphatidylinositol 3-kinase. J. Biol. Chem. 273, 3687-3694.
209. Yuan L., Yu W.M., Xu M. and Qu C.K. (2005). SHP-2 phosphatase regulates DNA damage-induced apoptosis and G2/M arrest in catalytically dependent and independent manners, respectively. J. Biol. Chem. 280, 42701-42706.
210. Zhan Y. and O'Rourke D.M. (2004). SHP-2-dependent mitogen-activated protein kinase activation regulates EGFRvIII but not wild-type epidermal growth factor receptor phosphorylation and glioblastoma cell survival. Cancer Res. 64, 8292-8298.
211. Zhang E.E., Chapeau E., Hagihara K. and Feng G.S. (2004). Neuronal Shp2 tyrosine phosphatase controls energy balance and metabolism. Proc. Natl. Acad. Sci. USA 101, 16064-16069.
212. Zhang J., Somani A.K., Watt S., Mills G.B. and Siminovitch K.A. (1999). The Src-homology domain 2-bearing protein tyrosine phosphatase-1 inhibits antigen receptor-induced apoptosis of activated peripheral T cells. J. Immunol. 162, 6359-6367.
213. Zhang S.Q., Tsiaras W.G., Araki T., Wen G., Minichiello L., Klein R. and Neel B.G. (2002). Receptor-specific regulation of phosphatidylinositol 3′-kinase activation by the protein tyrosine phosphatase Shp2. Mol. Cell. Biol. 22, 4062-4072.
214. Zou G.M., Chan R.J., Shelley W.C. and Yoder M.C. (2006). Reduction of shp-2 expression by small interfering RNA reduces murine embryonic stem cell-derived in vitro hematopaietic differentiation. Stem Cells 24, 587-594.
215. Zou G.M., Hu W.Y. and Wu W. (2007). TNF family molecule LIGHT regulates chemokine CCL27 expression on mouse embryonic stem cell-derived dendritic cells through NF-kappaB activation. Cell. Signal. 19, 87-92.